Comparing The Efficacy Of An Anti-Human VEGF-A Neutralizing Antibody Versus Bevacizumab On A Laser-Induced Choroidal Neovascularization (CNV) Rhesus Monkey Model

References

• Goody RJ, Hu W, Shafiee A, et al. Optimization of laser-induced chroidal neovascularization in African green monkeys. Exp Eye Res. 2011;92:464–472. doi:10.1016/j.exer.2011.03.00621414311
   PubMed Web of Science ®Google Scholar
• Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2012;120(3):338–346. doi:10.1001/archopht.120.3.338
   Google Scholar
• Zhang M, Zhang J, Yan M, et al. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovascularization in monkeys. Mol Vis. 2008;14:37–49.18246030
   PubMed Web of Science ®Google Scholar
• Lichtlen P, Lam TT, Nork TM, et al. Relative contribution of VEGF and TNF-α in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Invest Ophthalmol Vis Sc. 2010;51(9):4738–4745. doi:10.1167/iovs.09-489020393113
   PubMed Web of Science ®Google Scholar
• Lai K, Jin C, Tu S, et al. Intravitreal injection of 99Tc-MDP inhibits the development of laser-induced choroidal neovascularization in rhesus monkeys. Grafes Arch Clin Exp Ophthalmol. 2014;252:1049–1057. doi:10.1007/s00417-013-2559-1
   PubMed Web of Science ®Google Scholar
• Ding X, Patel M, Chan -C-C. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res. 2009;28(1):1–18. doi:10.1016/j.preteyeres.2008.10.00119026761
   PubMed Web of Science ®Google Scholar
• Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145(3):574–584.7521577
   PubMed Web of Science ®Google Scholar
• Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol. 2006;142(4):660–668. doi:10.1016/j.ajo.2006.05.06117011860
   PubMed Web of Science ®Google Scholar
• Van Asten F, Michels CTJ, Hoyng CB, et al. The cost-effectiveness of bevacizumab and aflibercept for the treatment of age-related macular degeneration-a cost-effectiveness analysis from a societal perspective. PLoS One. 2018;13(5):e0197670. doi:10.1371/journal.pone.019767029772018
   PubMed Web of Science ®Google Scholar
• Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci. 2008;49(2):522–527. doi:10.1167/iovs.07-117518234994
   PubMed Web of Science ®Google Scholar
• Rodríguez EB, Farah ME, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Progs Retin Eye Res. 2009;28(2):117–144. doi:10.1016/j.preteyeres.2008.11.005
   PubMed Web of Science ®Google Scholar
• Husain D, Kim I, Gauthier D, et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol. 2005;123:509–516. doi:10.1001/archopht.123.4.50915824225
   PubMed Web of Science ®Google Scholar
• CATT Research Group; Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–1908.21526923
   PubMed Web of Science ®Google Scholar
• Zhang Y, Han Q, Ru Y, et al. Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application. Drug Des Devel Ther. 2015;9:314–321.
   Web of Science ®Google Scholar
• Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye. 2011;25(6):661–672. doi:10.1038/eye.2011.6621455242
   PubMed Web of Science ®Google Scholar
• Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroideal neovascularization? Grafe’s Arch Clin Exp Ophthalmol. 2009;247(2):171–177. doi:10.1007/s00417-008-0936-y
   PubMed Web of Science ®Google Scholar
• Manzano RPA, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804–807. doi:10.1136/bjo.2006.10791217179168
   PubMed Web of Science ®Google Scholar
• Akar EE, Öner V, Küçükerdönmez C, et al. Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model. Int J Ophthalmol. 2013;6(2):136–140. doi:10.3980/j.issn.2222-3959.2013.02.0523638411
   PubMed Web of Science ®Google Scholar
• Pan CK, Durairaj C, Kompella UB, et al. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in rat model. J Ocul Pharmacol Ther. 2011;27(3):219–224. doi:10.1089/jop.2010.015821574814
   PubMed Web of Science ®Google Scholar
• Fuh G, Wu P, Liang WC, et al. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with Avastin Fab. J Biol Chem. 2006;281(10):6625–6631. doi:10.1074/jbc.M50778320016373345
   PubMed Web of Science ®Google Scholar
• Lin X, Wang Q, He M. Repeated retinal photocoagulation in monkeys for the optimization of laser-induced choroidal neovascularization model. Exp Eyes Res. 2019;184:1–7. doi:10.1016/j.exer.2019.03.020
   PubMed Web of Science ®Google Scholar
• Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparison of the intraocular tissue distribution, pharmacokinetics, and safety of 125 I-labeled full-length and fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27(5):536–544. doi:10.1177/01926233990270050710528633
   PubMed Web of Science ®Google Scholar
• Seo S, Suh W. Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization. Mol Vis. 2017;23:823–831.29225458
   PubMed Web of Science ®Google Scholar
• Novack GD. Translating drugs from animals to humans: do we need to prove efficacy? Trans Vis Sci Tech. 2013;2(6):1. doi:10.1167/tvst.2.6.1
   PubMed Web of Science ®Google Scholar
• Miki K, Miki A, Matsuoka M, et al. Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology. 2009;116(9):1748–1754. doi:10.1016/j.ophtha.2009.05.02019643496
   PubMed Web of Science ®Google Scholar
• Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007;48(6):2814–2823. doi:10.1167/iovs.06-117117525217
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binging and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–185. doi:10.1007/s10456-011-9249-622302382
   PubMed Web of Science ®Google Scholar